Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other financing activities (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Other financing activities data on record, last reported at $62000.0 in Q4 2025.

  • For Q4 2025, Other financing activities rose 104.13% year-over-year to $62000.0; the TTM value through Dec 2025 reached $478000.0, changed N/A, while the annual FY2025 figure was $478000.0, N/A changed from the prior year.
  • Other financing activities reached $62000.0 in Q4 2025 per VRDN's latest filing, down from $209000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $10.4 million in Q1 2024 and bottomed at -$9.0 million in Q3 2024.
  • Average Other financing activities over 5 years is $110615.4, with a median of $207000.0 recorded in 2025.
  • Peak YoY movement for Other financing activities: soared 236.94% in 2022, then plummeted 391.83% in 2024.
  • A 5-year view of Other financing activities shows it stood at -$1.1 million in 2021, then tumbled by 130.2% to -$2.5 million in 2022, then skyrocketed by 120.19% to $514000.0 in 2023, then tumbled by 391.83% to -$1.5 million in 2024, then soared by 104.13% to $62000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $62000.0 in Q4 2025, $209000.0 in Q3 2025, and $207000.0 in Q1 2025.